Q32 Bio director Mark Iwicki withdraws resignation, remains Board Chair and committee member

Q32 Bio Inc.

Mark Iwicki had previously notified intention to resign from Board effective Dec 31, 2025 to focus on CEO role at Inhibikase Therapeutics.
On Dec 17, 2025, Iwicki withdrew resignation with full Board support, effective immediately, citing reduced board commitments.
He will continue as Chair of the Board and Compensation Committee, and as a member of the Audit Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.